Table 1 Patient demographic and treatment characteristics; percentiles are listed parenthetically.
Characteristic | Â | Â | Series | Primary disease | Recurrent disease |
|---|---|---|---|---|---|
| Â | Â | Â | (n = 42) | (n = 33) | (n = 9) |
Age (yrs) | Â | Â | Â | Â | Â |
| Â | Median | Â | 60 | 63 | 46 |
|  | Range |  | 20–86 | 40–86 | 20–59 |
Sex | Â | Â | Â | Â | Â |
| Â | Male | Â | 27 (64) | 20 (60) | 7 (78) |
| Â | Female | Â | 15 (36) | 13 (40) | 2 (22) |
Surgery | Â | Â | Â | Â | Â |
| Â | Biopsy alone/unresectable | Â | 8 (19) | 6 (19) | 2 (22) |
| Â | Debulking/resection | Â | 34 (81) | 27 (81) | 7 (78) |
| Â | Â | Complete resection | 13(31) | 10 (30) | 3 (33) |
| Â | Â | Partial resection | 21(50) | 17 (51) | 4 (44) |
Chemotherapy | None | Â | 19 (45) | 17 (51) | 2 (22) |
| Â | Any agent | Â | 23 (55) | 16 (49) | 7 (78) |
| Â | Â | Carmustine (iv) | 5 (12) | 2 (6) | 3 (33) |
| Â | Â | Carmustine (wafer) | 2 (5) | 1 (3) | 1 (11) |
| Â | Â | Lomustine | 1 (2) | 1 (3) | - |
| Â | Â | Irinotecan | 3(7) | 2 (6) | 1 (11) |
| Â | Â | Penicillamine | 3 (7) | 3 (9) | - |
| Â | Â | Temozolomide | 9(21) | 7 (21) | 2 (22) |
IMRT technique | Â | Â | Â | Â | Â |
| Â | IMRT Only | Â | 30 (72) | 22 (66) | 8 (89) |
| Â | 3DCRT + IMRT boost | Â | 12 (28) | 11 (33) | 1 (11) |